Astrazeneca (AZN) Stock
Global pharmaceutical company with strong cancer and respiratory portfolio. Here's the price, business snapshot, and what's worth knowing about Astrazeneca in June 2026.
AstraZeneca PLC (AZN) is a large‑cap global biopharmaceutical company focused on discovery, development and commercialisation of prescription medicines, with particular strength in oncology, cardiovascular, renal & metabolic (CVRM), and respiratory therapies. The firm combines a broad marketed portfolio with an active R&D pipeline and significant investment in biologics and precision medicines. For investors, key considerations include steady revenue from established drugs, growth driven by newer oncology and rare‑disease launches, and continued R&D spend that can both support long‑term value and create near‑term earnings variability. The company operates globally, exposing it to different regulatory and pricing environments and currency movements. AstraZeneca has historically paid dividends, but dividend levels and share price can fluctuate with trial outcomes, patent expiries and competition. This summary is educational only — not personalised investment advice — and investors should weigh growth potential against clinical, regulatory and commercial risks.
Why It’s Moving
AstraZeneca holds firm as analysts focus on its pipeline momentum and upcoming readouts.
- Analysts continue to flag a sizable cluster of Phase III readouts ahead, which keeps expectations elevated around possible pipeline-driven upside rather than simple valuation expansion.
- The stock’s forecast profile remains constructive in the latest coverage, reinforcing the view that investors are still pricing in execution across AstraZeneca’s oncology and broader drug portfolio.
- With no major company-specific event in the last week surfaced here, sector-wide biotech sentiment and anticipation of future clinical data are likely doing most of the work behind recent moves.
AstraZeneca holds firm as analysts focus on its pipeline momentum and upcoming readouts.
- Analysts continue to flag a sizable cluster of Phase III readouts ahead, which keeps expectations elevated around possible pipeline-driven upside rather than simple valuation expansion.
- The stock’s forecast profile remains constructive in the latest coverage, reinforcing the view that investors are still pricing in execution across AstraZeneca’s oncology and broader drug portfolio.
- With no major company-specific event in the last week surfaced here, sector-wide biotech sentiment and anticipation of future clinical data are likely doing most of the work behind recent moves.
When is the next earnings date for ASTRAZENECA PLC (AZN)?
The next earnings date for AZN is expected on July 27, 2026, before the market opens. It will cover Q2 2026 results. AstraZeneca has not formally confirmed the date, but this is the consensus estimate based on its historical reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AstraZeneca's stock, expecting it to rise towards the target price of $114.08.
Financial Health
AstraZeneca is performing well with strong profits, cash flow, and revenue, indicating solid financial stability.
Dividend
AstraZeneca's average dividend yield of 2.65% makes it a reasonable choice for investors seeking dividends. If you invested $1000 you would be paid $26.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
AMNEAL PHARMACEUTICALS INC
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
Baskets Featuring AZN
Pharma Manufacturing | What's Next After TrumpRx
GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.
Published: 14 March 2026
Explore BasketBiotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketBlood Thinner Breakthrough Explained | Market Overview
Bayer's successful Phase III trial for its new blood thinner has demonstrated a significant reduction in stroke recurrence. This breakthrough positions the company favorably against competitors and highlights an investment opportunity in the evolving landscape of cardiovascular treatments.
Published: 6 February 2026
Explore BasketPharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketCancer Therapies: What's Next After 100% Response Rate
Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published: 7 December 2025
Explore BasketUK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Published: 2 December 2025
Explore BasketM&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published: 15 November 2025
Explore BasketGlobal Medtech UAE Healthcare Investment Basket 2025
The United Arab Emirates is making significant investments to upgrade its medical infrastructure, aiming to become a global healthcare destination. This basket provides exposure to the international US and EU-listed companies in pharmaceuticals, medtech, and digital health that supply this ambitious national project.
Published: 12 November 2025
Explore BasketPharma Onshoring Boom: Investment Risk Considerations
AstraZeneca is building a major new manufacturing plant in the U.S., responding to policy pressures for domestic production. This signals a broader trend of onshoring pharmaceutical manufacturing, creating opportunities for companies that build and equip these advanced facilities.
Published: 10 October 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: 23 September 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: 10 September 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: 3 August 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: 1 August 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: 15 July 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: 2 July 2025
Explore BasketMade in the UK
Diversify your portfolio with some of Britain's most established companies. Our analysts have carefully selected these UK powerhouses that span multiple industries from banking to pharmaceuticals, energy to consumer goods.
Published: 10 May 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: 6 May 2025
Explore BasketUK-US Trade Deal
These carefully selected UK stocks could benefit from the newly announced US-UK trade agreement, the first under Trump's second administration. Our professional analysts have identified companies with potential upside as tariffs are cut on British exports like steel, aluminum, and more.
Published: 3 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline drives growth
AstraZeneca’s R&D pipeline, especially in oncology and precision medicines, can support future revenue, though trial outcomes and approvals are uncertain.
Global footprint matters
Wide geographic reach diversifies revenue but brings exposure to regulatory, pricing and currency risks that can affect results.
Innovation and spending
Heavy investment in biologics and new modalities underpins long‑term potential while creating earnings variability in the near term.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
